Literature DB >> 24183701

Interleukin-1α.

Peleg Rider1, Yaron Carmi2, Elena Voronov3, Ron N Apte3.   

Abstract

Although the IL-1α molecule has long been recognized, information about its distinct role in various diseases is limited, since most clinical studies have focused on the role of IL-1β. Despite triggering the same IL-1 receptor as does IL-1β, there is, however, a distinct role for IL-1α in some inflammatory diseases. IL-1α is a unique cytokine since it is constitutively present intracellularly in nearly all resting non-hematopoietic cells in health as well as being up-regulated during hypoxia. During cell necrosis, IL-1α functions as an alarm molecule and thus plays a critical role early in inflammation. Following its release from damage tissue cells, IL-1α mediates neutrophil recruitment to the site of injury, inducing IL-1β, other cytokines and chemokines from surrounding resident cells. Another unique attribute of IL-1α is its nuclear localization sequence present in the N-terminal half of the precursor termed the propiece. The IL-1α propiece translocates into the nucleus and participates in the regulation of transcription. Therefore, IL-1α, like IL-1 family members IL-33 and IL-37, is a 'dual-function' cytokine binding to chromatin as well as to its cell surface receptor. Some cancer cells can express membrane IL-1α, which can increase immunogenicity of tumor cells and serve in anti-tumor immune surveillance and tumor regression. However, in the tumor microenvironment, precursor IL-1α released from dying tumor cells is inflammatory and, similar to IL-1β, increases tumor invasiveness and angiogenesis.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24183701     DOI: 10.1016/j.smim.2013.10.005

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  58 in total

Review 1.  Interleukin 1α and the inflammatory process.

Authors:  Nelson C Di Paolo; Dmitry M Shayakhmetov
Journal:  Nat Immunol       Date:  2016-07-19       Impact factor: 25.606

Review 2.  The pediatric sepsis biomarker risk model: potential implications for sepsis therapy and biology.

Authors:  Matthew N Alder; Christopher J Lindsell; Hector R Wong
Journal:  Expert Rev Anti Infect Ther       Date:  2014-04-22       Impact factor: 5.091

Review 3.  Danger-Associated Molecular Patterns (DAMPs): the Derivatives and Triggers of Inflammation.

Authors:  Seema Patel
Journal:  Curr Allergy Asthma Rep       Date:  2018-09-28       Impact factor: 4.806

Review 4.  The NLRP3 inflammasome in acute myocardial infarction.

Authors:  Stefano Toldo; Antonio Abbate
Journal:  Nat Rev Cardiol       Date:  2017-11-16       Impact factor: 32.419

Review 5.  Interleukin 33 is a guardian of barriers and a local alarmin.

Authors:  Nikolas T Martin; Michael U Martin
Journal:  Nat Immunol       Date:  2016-02       Impact factor: 25.606

6.  Elevated serum levels of interleukin-1β and interleukin-33 in patients with systemic sclerosis in Chinese population.

Authors:  Y-J Zhang; Q Zhang; G-J Yang; J-H Tao; G-C Wu; X-L Huang; Y Duan; X-P Li; D-Q Ye; J Wang
Journal:  Z Rheumatol       Date:  2018-03       Impact factor: 1.372

7.  IL-1 in Colon Inflammation, Colon Carcinogenesis and Invasiveness of Colon Cancer.

Authors:  Elena Voronov; Ron N Apte
Journal:  Cancer Microenviron       Date:  2015-12-19

8.  Expression and regulation of alarmin cytokine IL-1α in human retinal pigment epithelial cells.

Authors:  Zong-Mei Bian; Matthew G Field; Susan G Elner; Victor M Elner
Journal:  Exp Eye Res       Date:  2018-03-15       Impact factor: 3.467

9.  Critical role of IL-1α in IL-1β-induced inflammatory responses: cooperation with NF-κBp65 in transcriptional regulation.

Authors:  Anil K Singh; Sabrina Fechtner; Mukesh Chourasia; Jerry Sicalo; Salahuddin Ahmed
Journal:  FASEB J       Date:  2018-10-01       Impact factor: 5.191

10.  Pharmacological inhibition of caspase-8 limits lung tumour outgrowth.

Authors:  Michela Terlizzi; Vincenzo Giuseppe Di Crescenzo; Giuseppe Perillo; Antonio Galderisi; Aldo Pinto; Rosalinda Sorrentino
Journal:  Br J Pharmacol       Date:  2015-06-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.